User profiles for Oliver Langer
 | Oliver LangerMedical University of Vienna Verified email at meduniwien.ac.at Cited by 6292 |
Blood–brain barrier P-glycoprotein function in Alzheimer's disease
A major pathological hallmark of Alzheimer's disease is accumulation of amyloid-β in senile
plaques in the brain. Evidence is accumulating that decreased clearance of amyloid-β from …
plaques in the brain. Evidence is accumulating that decreased clearance of amyloid-β from …
P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study
Background Studies in rodent models of epilepsy suggest that multidrug efflux transporters at
the blood–brain barrier, such as P-glycoprotein, might contribute to pharmacoresistance by …
the blood–brain barrier, such as P-glycoprotein, might contribute to pharmacoresistance by …
Pgp‐Mediated Interaction Between (R)‐[11C]Verapamil and Tariquidar at the Human Blood–Brain Barrier: A Comparison With Rat Data
Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction
between a microdose of (R)‐[ 11 C]verapamil (a P‐glycoprotein (Pgp) substrate) and escalating …
between a microdose of (R)‐[ 11 C]verapamil (a P‐glycoprotein (Pgp) substrate) and escalating …
Pharmacoresistance in Epilepsy: A Pilot PET Study with the P‐Glycoprotein Substrate R‐[11C]verapamil
Purpose and Methods: Regional overexpression of the multidrug transporter P‐glycoprotein
(P‐gp) in epileptic brain tissue may lower target site concentrations of antiepileptic drugs …
(P‐gp) in epileptic brain tissue may lower target site concentrations of antiepileptic drugs …
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil …
Purpose Overactivity of the multidrug efflux transporter P-glycoprotein (P-gp) at the blood-brain
barrier (BBB) is believed to play an important role in resistance to central nervous system …
barrier (BBB) is believed to play an important role in resistance to central nervous system …
[HTML][HTML] Phase 0/microdosing approaches: time for mainstream application in drug development?
Phase 0 approaches — which include microdosing — evaluate subtherapeutic exposures
of new drugs in first-in-human studies known as exploratory clinical trials. Recent progress …
of new drugs in first-in-human studies known as exploratory clinical trials. Recent progress …
Approaches using molecular imaging technology—use of PET in clinical microdose studies
CC Wagner, O Langer - Advanced drug delivery reviews, 2011 - Elsevier
Positron emission tomography (PET) imaging uses minute amounts of radiolabeled drug
tracers and thereby meets the criteria for clinical microdose studies. The advantage of PET, …
tracers and thereby meets the criteria for clinical microdose studies. The advantage of PET, …
Tariquidar-induced P-glycoprotein inhibition at the rat blood–brain barrier studied with (R)-11C-verapamil and PET
The multidrug efflux transporter P-glycoprotein (P-gp) is expressed in high concentrations at
the blood–brain barrier (BBB) and is believed to be implicated in resistance to central …
the blood–brain barrier (BBB) and is believed to be implicated in resistance to central …
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood–brain barrier with (R)-11C-verapamil and PET
Tariquidar, a potent, nontoxic, third-generation P-glycoprotein (P-gp) inhibitor, is a possible
reversal agent for central nervous system drug resistance. In animal studies, tariquidar has …
reversal agent for central nervous system drug resistance. In animal studies, tariquidar has …
Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in …
Elacridar (ELC) and tariquidar (TQD) are generally thought to be nontransported inhibitors of
P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP), but recent data indicate …
P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP), but recent data indicate …